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Report by the Comissió d’Avaluació Econòmica i Impacte Pressupostari, 
CAEIP (Economic Evaluation and Budget Impact Commission), of 
Catsalut,   about the new medicines for the control of the glucose in type 
2 diabetes mellitus commercialized in Catalonia 
The diabetes mellitus is a pathology with a prevalence known in Catalonia of 
5,9%1 and its appearance is associated to macro and microvascular 
complications. 
The objective of the treatment of the patients with type 2 diabetes mellitus is to 
improve the quantity and quality of life of the patients in order to retard the 
appearance of the derivative complications of the illness, as much as possible. 
In the pharmotherapeutic field, during the last years new drugs have been 
incorporated into the pharmaceutical offer. Given the prevalence of the pathology 
and its priority in health is considered indispensable to increase the efficiency in 
the utilization of the drugs for the control of the glucose in the type 2 diabetes 
mellitus (conventional and new alternatives) in the patients in Catalonia to 
improve the results in health. 
So, given the results of the systematic Revision of economic evaluations of the 
new medicines for the control of the glucose in type 2 diabetes mellitus 
commercialized in Spain2, another available evidence3 and the appraisal of the 
members of the CAEIP, the CAEIP recommends the following measures for an 
efficient selection of medicines for the treatment of the type 2 diabetes mellitus: 
• Metformin as a pharmacological measure of first line in the diabetic 
patients type 2 being the option more cost-effective in the patients who do 
not control themselves with the changes in the lifestyle (diet and exercise). 
 In those situations in that either metformin not the changes in the lifestyle 
are sufficient, it is recommended to add a second drug. Among the 
different options, the sulfonylureas are an effective option while less 
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costly than the other alternatives available (inhibitors of the dipeptil 
peptidase- DPP-4- and glitazones) and, therefore, they are the option 
of preference. 
 
  In the patients who require insulin, insulin is recommended initially at 
night and insulin NPH can be used like an effective option and less costly 
than other alternatives. Among the insulins of prolonged action:  glargine 
and detemir there is not any dominant option according to criteria of cost-
effectiveness. Regarding the analogous of GLP-1, exenatide, from the 
cost-effectiveness perspective, it seems more cost-effective in front to 
glargina in patients with type 2 diabetes mellitus with sustained pancreatic 
reserve and an  BMI > 30. However, exenatide only have comparative 
studies with glargine insulin as an active comparator. 
 
 
These recommendations do not have to imply discarding the selection of the 
therapeutic alternative that, according to the clinical criterion, one generates 
more effectiveness of the treatment in determinate patients. 
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